Drugs / Tafoxiparin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00710242 | Apr 2007 → Mar 2009 | pregnancy disorder | Dilafor AB | Completed | Missed primary |
Press releases naming this drug 12 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tafoxiparin | “Tafoxiparin, a novel drug candidate for cervical ripening and labor augmentation: results from 2 randomized, placebo-controlled studies.” PMID 38462256 ↗ May 2023 |
| Modality | Other / unclassified | “Tafoxiparin is a depolymerized form of heparin with a molecular structure that eliminates the anticoagulant effects of heparin.” PMID 38462256 ↗ May 2023 |
| Route | Subcutaneous | “In study 1, patients at 38 to 40 weeks of gestation received 60 mg tafoxiparin or placebo daily as 0.4 mL subcutaneous injections until labor onset (maximum 28 days).” PMID 38462256 ↗ May 2023 |